The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ALIBABA GROUP HLDG LTD | SPONSORED ADS | 01609W102 | 604,404 | 6,968 | SH | SOLE | N/A | 6,968 | 0 | 0 | |
ALIBABA GROUP HLDG LTD | SPONSORED ADS | 01609W102 | 18,832,000 | 220,000 | SH | Call | SOLE | N/A | 220,000 | 0 | 0 |
ALPHABET INC | CAP STK CL A | 02079K305 | 1,962,900 | 15,000 | SH | Call | SOLE | N/A | 15,000 | 0 | 0 |
YS BIOPHARMA CO LTD | *W EXP 03/15/202 | G9845F117 | 19,250 | 550,000 | SH | SOLE | N/A | 550,000 | 0 | 0 |